|Bid||14.50 x 800|
|Ask||19.50 x 3000|
|Day's Range||16.58 - 16.95|
|52 Week Range||13.53 - 19.84|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||30.04|
|Earnings Date||Jan 24, 2019|
|Forward Dividend & Yield||0.50 (2.99%)|
|1y Target Est||17.00|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018. The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment. The Life Science segment is expected to post revenue about in line with first quarter 2018. To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5086695.
Meridian Bioscience, Inc. (VIVO) today announced that it has received FDA clearance for its new Alethia™ CMV Molecular Amplification Test (formerly, the illumigene brand). This assay is designed to specifically detect congenital Cytomegalovirus (cCMV) infection in newborns from an easy-to-collect saliva sample. Alethia CMV is the first qualitative test in a molecular amplification format, FDA-cleared for cCMV testing in newborns.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The U.S. Food and Drug Administration approved on Friday the first test - a diagnostic from Meridian Bioscience Inc - to help detect a type of herpes virus in newborns. Meridian's Alethia CMV Assay Test System detects cytomegalovirus (CMV) DNA from saliva swabs and won approval for use in babies younger than 21 days of age infected during pregnancy. Over half of adults have been infected with CMV by the age of 40, according to the Centers for Disease Control and Prevention.
Meridian Bioscience Inc is an integrated life science company. The dividend yield of Meridian Bioscience Inc stocks is 2.69%. Meridian Bioscience Inc had annual average EBITDA growth of 2.00% over the past ten years.
MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations in the fiscal year ended June 30.
Investors who want to cash in on Meridian Bioscience Inc’s (NASDAQ:VIVO) upcoming dividend of US$0.13 per share have only 2 days left to buy the shares before its ex-dividend date, Read More...
In September 2018, Meridian Bioscience Inc (NASDAQ:VIVO) announced its most recent earnings update, which suggested that the business gained from a robust tailwind, eventuating to a double-digit earnings growth of Read More...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 25.00% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cincinnati-based company said it had profit of 13 cents. Earnings, adjusted for one-time gains and costs, came to 20 cents per share. The results beat Wall Street expectations. ...
CINCINNATI, Nov. 08, 2018 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2018..
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning about how to value company based on its Read More...
Two important questions to ask before you buy Meridian Bioscience Inc (NASDAQ:VIVO) is, how it makes money and how it spends its cash. This difference directly flows down to how Read More...
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Historically, Meridian Bioscience Inc (NASDAQ:VIVO) has paid a dividend toRead More...
Does the share price for Meridian Bioscience Inc (NASDAQ:VIVO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by projecting its future cash flows and then discountingRead More...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 5.88% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cincinnati-based company said it had net income of 16 cents per share. Earnings, adjusted for non-recurring costs, were 18 cents per share. The results exceeded Wall Street expectations. The average ...